Shares of Moderna (NASDAQ: MRNA) were rising 3.3% as of 10:59 a.m. EDT on Monday. This gain came after the Financial Times reported new forecasts from health data analytics company Airfinity that project Moderna's COVID-19 vaccine could generate sales of $38.7 billion in 2022. Investors might be justified in jumping aboard the Moderna train if Airfinity's 2022 estimate is right.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting